Chemoresistance remains a major challenge for the treatment of glioma. In this study, we investigated the role of Clock 1 (Clk1), which encodes an enzyme that is necessary for ubiquinone biosynthesis in glioma chemoresistance in vitro. The results showed that Clk1 was highly expressed in GL261 mouse glioma cells which were most sensitive to 1,3Bis (2-chloroethyl) 1 nitrosourea (BCNU) while was low expressed in BCNU resistant cells such as glioma cancer stem cells, T98G, U87MG and U251 glioma cells. Knockdown of Clk1 in GL261 glioma cells significantly reduced BCNU-or cisplatin-induced cell apoptosis, whereas the proliferative activity and the expression of multidrug resistance-related genes including MDR1, O6-methylguanine-DNA methyltransferase, and GSTP1 were not changed. When Clk1 was re-expressed in Clk1 knockdown GL261 glioma cells, the BCNU sensitivity was restored. The mechanistic study revealed that knockdown of Clk1 in GL261 glioma cells increased aerobic glycolysis including high glucose consumption, lactate production, and up-regulation of glycolysis-associated genes. Inhibition of glycolysis can reverse the chemoresistance elicited by Clk1 knockdown in GL261 cells. Moreover, knockdown of Clk1 induced HIF-1a expression in GL261 glioma cells which was found to be mediated by AMPactivated protein kinase (AMPK)/mechanistic target of rapamycin (mTOR) signaling pathway. Both metformin and rapamycin reversed the chemoresistance of Clk1 knockdown GL261 glioma cells. Over-expression of Clk1 significantly increased the sensitivity of T98G or U251 human glioblastoma cells to BCNU which was accompanied by decreased lactate secretion, decreased expression of HIF-1a, AMPK activation, and inhibition of mTOR pathway. Inhibition of glycolysis or activation of AMPK did not alter Clk1 expression in variant glioma cell lines suggesting that aerobic glycolysis is not an upstream event of Clk1 expression in glioma cells. Taken together, our results revealed, for the first time, that mitochondrial Clk1 regulated chemoresistance in glioma cells through AMPK/mTOR/HIF-1a mediated glycolysis pathway.
concomitant and adjuvant chemotherapy is standard treatment for malignant glioma (Fan et al. 2014) . 1, 3-Bis (2-chloroethyl)-1-nitrosourea (BCNU), an alkylating agent, is commonly used in the chemotherapy of malignant glioma. Although standard treatment could have reached effectiveness, the prognosis is poor because of high frequency of local relapse and drug resistance (Lu and Shervington 2008) . Various mechanisms are proposed to be involved in the development of chemoresistance of glioma, such as the increased expression of anti-apoptotic-related genes, drug efflux associated gene, DNA damage repair gene like O6-methylguanine-DNA methyltransferase (MGMT) (Sarkaria et al. 2008; Zheng et al. 2009; Mould et al. 2014) and detoxifying enzyme glutathione S-transferase pi 1. Recently, it was demonstrated that tumor-induced hypoxic environment, cancer stem cells, mitochondrial dysfunction, and glycolytic metabolisms also participated in acquired and intrinsic drug resistances of malignant glioma (Haar et al. 2012) . Nevertheless, the precise molecular and cellular mechanisms of glioma resistance to chemotherapy remain to be elucidated. Thus, research focused on the cellular and molecular mechanisms of glioma chemoresistance would be of great importance to a more effective treatment of malignant glioma.
Mitochondrial hydroxylase Clk1 encodes a key regulatory component of the conserved enzyme that is involved in the biosynthesis of coenzyme Q (Marbois and Clarke 1996) . Coenzyme Q transfers electrons from complex I or complex II to complex III in mitochondrial inner membrane, which is essential for mitochondrial respiration (Lapointe and Hekimi 2008) . Clk1 has numerous biological roles in cellular processes. A loss of functional mutation of Clk1 gene in yeasts, nematodes, and mice result in accumulation of biosynthetic intermediate demethoxyubiquinone instead of producing COQ7 (Stepanyan et al. 2006) . Knockout studies in mice and Caenorhabditis elegans demonstrate that complete loss of Clk1 leads to embryonic lethality (Nakai et al. 2001; Liu et al. 2005) . However, partial inactivation of Clk1 in heterozygous animals (Clk1 +/À mutant) results in prolonged life span, slowdown of developmental processes, and slowing of rhythmic behaviors (Lakowski and Hekimi 1996) . A loss of function of Clk1 elicits mitochondrial dysfunction such as decreased mitochondrial oxygen consumption, impaired electron transport, reduced mitochondrial ATP synthesis, and an increase in the production of mitochondrial reactive oxygen species (mtROS) (Lapointe and Hekimi 2008; Lapointe et al. 2009 ). It was also reported that nuclear form of Clk1 regulates ROS metabolism and mitochondrial unfolded protein response via chromatin mechanisms (Monaghan et al. 2015) . (Wang et al. 2010) demonstrated that Clk1 deficiency leads to enhanced inflammatory response in vitro and in vivo. Recently, we also reported that AMP-activated protein kinase (AMPK) inactivation triggers activation of the mechanistic target of rapamycin (mTOR)/HIF-1a and ROS/HIF-1a signaling pathway are involved in Clk1-mediated microglial activation and glycolytic reprogramming (Gu et al. 2017) . Moreover, it was also demonstrated that Clk1 À/À embryonic stem cells protect from oxidative stress and DNA damages induced by anti-cancer drug etoposide or anisomycin (Liu et al. 2005) .
In the nematode C. elegans, loss of Clk1 leads to more resistance to the cytotoxic peptides hemiasterlin (Zubovych et al. 2010) . Nevertheless, the role of Clk1 in chemoresistance of malignant tumor cells and the underling molecular mechanisms have not yet been explored. Here, we reported that Clk1 level is correlated with the sensitivity of glioma cells to chemotherapeutic agents. The mechanistic study demonstrated that aerobic glycolysis mediated by AMPK/mTOR/HIF1a may contribute to the chemoresistance of Clk1 deficient cells.
Materials and methods

Chemicals and reagents
Carmustine (BCNU), cisplatin (DDP), 3-bromopyruvate (3-BrPA), 2-deoxy-D-glucose (2-DG), rotenone, 3-nitropropionic acid (3-NP), metformin, rapamycin, and antimycin were purchased from SigmaAldrich (St. Louis, MO, USA). Lipofectamine â RNAi MAX and lipofectamine 2000 were purchased from Invitrogen (Carlsbad, CA, USA). Primary antibody for Clk1 (RRID:AB_2082207) was purchased from Proteintech Group Inc. (Chicago, IL, USA). Cleaved casepase 3 (RRID:AB_2341188), total caspase 3 (RRID: AB_331439), cleaved poly (ADP-ribose) polymerase (PARP) (RRID:AB_2160592), total PARP (RRID:AB_2160739), HK-2 (RRID:AB_823520), p-mTOR (Ser2448) (RRID:AB_330970), mTOR (RRID:AB_330978), p-S6K (Thr389) (RRID:AB_330944), S6K (RRID:AB_10695156), p-S6 (RRID:AB_331679), S6 (RRID: AB_331355), p-Akt (Ser473) (RRID:AB_329825), Akt RRID: AB_329827), p-AMPK (Thr172) (RRID:AB_330331), and AMPK (RRID:AB_330331) were obtained from Cell Signaling Technology (Beverly, MA, USA). Anti-pyruvate dehydrogenase kinase 1 (PDK1) (RRID:AB_2161138),glucose transporter 1 (RRID: AB_2239463), and anti-lactate dehydrogenase A (LDHA) antibody (RRID:AB_2137193) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-HIF-1a monoclonal antibody (RRID:AB_10001154) was obtained from Novus Biologicals (Littleton, CO, USA).
Cell culture and establishment of Clk1-silenced glioma cell line U87MG (human, glioblastoma-astrocytoma, grade IV,RRID: CVCL_0022), T98G (human, glioblastoma, grade IV,RRID: CVCL_0556), U251 (human, glioblastoma, grade III,RRID: CVCL_0021), C6 (rat glioma cell,RRID:CVCL_0194), and GL261 (murine glioma,RRID:CVCL_Y003) cell lines were purchased from The Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). All cells were cultured in Dulbecco's modified Eagle's media supplemented with 10% fetal calf serum (FBS) and maintained at 37°C in a humidified atmosphere of 95% air and 5% CO 2 . SU2 glioma stem cell lines (Wang et al. 2016) were isolated from a 52-year-old female patient (glioblastoma, grade IV) who had received two operations with 6 months interval because of the rapid re-growth of tumor. The cells were grown in serum-free Dulbecco's modified Eagle's media/F12 (Gibco Life Technologies, Waltham, MA, USA) supplemented with recombinant human fibroblast growth factor (20 ng/mL; Invitrogen), recombinant human epidermal growth factor (20 ng/mL; Invitrogen), and 1% N 2 supplement (Gibco Life Technologies). Cells were fed by changing half of the medium every 3 days and were enzymatically dissociated into single cells for passage when they were large in size and high in density. Differentiated SU2 cells were cultured in DF12 supplemented with 5% FBS. Our study was approved by the Institutional Ethics Review committee of Soochow University.
Establishment of stable GL261 cell line expressing shClk1
The shRNA targeting the mRNA encoding Clk1 was obtained from Gene Pharma (Shanghai, China). Targeting sequence is as follows:
Briefly, GL261 cells were plated in six-well plates and transfected with 2 lg of shRNA construct using lipofectamine 2000 according to the manufacturer's protocol. At 24 h post-transfection, cells were cultured in the medium containing 800 lg/mL G418 and the stable expressing shRNA clones were selected.
Cell viability and proliferation assay
Cell viability was measured by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Individual cells were seeded in 96-well plates at a density of 2 9 10 4 cells/well in triplicate. After drug treatment for 24 h, the cell culture medium was removed and then incubated with 30 lL of 0.5 mg/mL 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide for 4 h at 37°C. Then, culture medium was carefully removed followed by addition of 100 lL dimethylsulfoxide to dissolve the purple crystals. Finally, the absorbance was read at 570 nm on a microplate reader (Multiskan MK3; Thermo Scientific, Waltham, MA, USA). For the growth curve analysis, cells were plated in 24-well plates (0.5 9 10 4 cells/ well) in triplicate. At the indicated times, the cells were detached, and counted by a hemocytometer.
Semi-quantitative reverse-transcription polymerase chain reaction Total RNA was extracted with TRIzol (TaKaRa, Da lian, China) and reverse-transcribed in the presence of a poly-A polymerase with an oligo-dT adaptor. The mRNA for genes of interest was quantitated with using PCR kit (TaKaRa) according to the manufacturer's protocol. The primers used in the study are shown in Table 1 .
Western blot
Cultured cells were harvested and lysed with NP-40 lysis buffer for total protein extraction. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and then transferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The membrane was blocked with 5% milk in Trisbuffered saline with Tween (TBST) buffer (TBS + 0.05% v/v Tween-20), and probed for protein of interest with a specific primary antibody overnight at 4°C, followed by incubation with a secondary antibody for 1 h at 25°C. Immune complexes were visualized using the enhanced chemiluminescence system (Millipore). To verify equal protein loading and transfer, membranes were stripped with stripping buffer (Beyotime Biotechnology, Shanghai, China) and reprobed with anti-a-tubulin antibody.
Metabolic levels: glucose consumption, lactate production, and ADP/ATP ratio A glucose assay kit (BioAssay Systems, Hayward, CA, USA) was used to measure the glucose concentrations in the culture medium samples, according to manufacturer's instructions. The absorbance of the colored complex at 620 nm was converted into glucose concentration using a calibration curve from the series of glucose standards. A lactate assay kit (ECLC-100; BioAssay Systems) was used to measure lactate concentrations in the culture medium samples, according to manufacturer's instructions. Lactate assay works by the principle that the tetrazolium salt iodonitrotetrazolium chloride (INT) was reduced in a NADH-coupled enzymatic reaction to form a water-soluble formazan color product.
The ATP/ADP ratio was measured in whole-cell lysates using an ATP/ADP Assay Kit (Sigma, St Louis, MO, USA) according to manufacturer's instructions.
Cellular oxygen consumption and extracellular acidification Cellular extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were, respectively, measured by a Seahorse XFe24 analyzer (Seahorse Bioscience, North Billerica, MA, USA). Cells were seeded at 5 9 10 4 cells per well in the XFe24 cell culture microplates and further incubated at 37°C with 5% CO 2 . The sensor cartridge for the XFe24 analyzer was hydrated in a 37°C non-CO 2 incubator a day before experiment. The ECAR values were calculated after sequential injections of glucose (10 mM) for 24 min, oligomycin (1 lM) for 24 min, and 2-DG (50 mM) for 24 min. Seahorse XFe24 analyzer was run using the 8 min cyclic protocol commands (mix for 3 min, wait for 2 min, and measure for 3 min). For the OCR assay, the injection port A on the sensor cartridge was loaded with 1.5 mM oligomycin (complex vs. inhibitor), 2 lM carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) was loaded to port B and 0.5 lM rotenone/antimycin A (inhibitors of complex I and complex III) was loaded to port C. To allow comparison between different experiments, data were expressed as the rate of oxygen consumption in pmol/min or the rate of extracellular acidification in mpH/min, normalized to cell protein in individual wells determined by the Bradford protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Gene Pharma. GL261 cells were transfected with 50 nM siRNA for 24 h, followed by treatments. RNA and protein knockdown were assessed by RT-PCR and western blot analysis.
RNA interference
Construction of the Clk1 expression plasmids
The full-length cDNA for human (NM_016138) or mouse synthesis reaction was performed using human cDNA library. The human cDNA was cloned into pcDNA3.1 plasmid. The mouse cDNA was cloned into pcDNA3.1-His plasmid and then mutated with the Muta-direct site-directed mutagenesis kit (SDM-15, SBS; Genetech, Shanghai, China), following primers: forward 5 0 -GCTCCCGCGT ACGCCTTATTGAAAAGGATTATC-3 0 and reverse 5 0 -GATA ATCCTTTTCAATAAGGCGTACGCGGGAGC-3 0 , while it mutanted at the binding site of shRNA Clk1 targeting.
Statistical analysis
All data were expressed as means AE standard deviation (SD), unless otherwise specified. Data sets were examined by analysis of variance (ANOVA) and Dunnett's test (when required). Differences were considered significant at p ˂ 0.05.
Results
Clk1 level correlates with the chemosensitivity of glioma cells We first measured the Clk1 expression level in different glioma cell lines such as U251, U87MG, T98G, GL261, and C6. As shown in Fig. 1 (a), Clk1 expression was higher in GL261 glioma cells as compared with other cell lines (Fig. 1a) . Interestingly, when exposed to BCNU, GL261 glioma cells exhibited a sensitivity much higher than those cell lines with lower Clk1 expression levels (Fig. 1b) , implicating that Clk1 level could be related to the chemoresistance of glioma cells. Since cancer stem cells are naturally resistant to anti-cancer drug, next we examined the expression of Clk1 in SU2 glioma cancer stem cells. Consistent with the observation from cell lines, SU2 glioma cancer stem Fig. 1 Expression of Clk1 in variant glioma cell lines and glioma cancer stem cells that display different chemo-sensitivities to 1,3-Bis (2-chloroethyl)-1-nitrosourea (BCNU). (a) Total proteins were isolated from U251, U87MG, T98G, GL261, and C6 glioma cells and then subject to western blot for the detection of Clk1 protein levels (left). Expression of Clk1 was quantified by densitometric analysis and normalized to a-tubulin (right). (b) Glioma cell lines U251, U87MG, T98G, GL261, and C6 were treated with BCNU (0.6-1.2 mM). The cell viability was measured by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay after treatment with indicated concentration of BCNU for 24 h. (c) Total proteins were isolated from glioma cancer stem cell SU2 (SU2s) or differentiated SU2 (SU2d) and then subject to western blot for the detection of Clk1 protein levels (left). Expression of Clk1 was quantified by densitometric analysis and normalized to a-tubulin (right). (d) Glioma cancer stem cell SU2 (SU2s) or differentiated SU2 (SU2d) was treated with BCNU (1-1.6 mM) for 24 h. The cell viability was determined by MTT assay. Data are presented as mean AE SD (n = 3), and are representative of three independent experiments. *p < 0.05, **p < 0.01, compared to SU2d cells. cells expressed a relative lower level of Clk1 and displayed more resistance to BCNU compared to the differentiated SU2 cells (Fig. 1c and d) .
Knockdown of Clk1 suppressed the sensitivity of GL261 glioma cells to anti-cancer drug As the Clk1 was highly expressed in the BCNU-sensitive GL261 glioma cells, we hypothesized that the level of Clk1 is related to the chemoresistance of those cells. To test this hypothesis, we examined if knockdown of Clk1 would promote the chemoresistance of GL261 glioma cells. Knockdown of Clk1 in GL261 glioma cells was achieved by transfection with shRNA targeting Clk1. The expression of Clk1 in GL261 cells was determined by RT-PCR and western blot ( Fig. 2a and b) . The results showed that knockdown of Clk1 significantly decreased the sensitivity of GL261 glioma cells to BCNU ( Fig. 2c and e) or DDP ( Fig. 2d and f) treatment. Since shClk1-2 was more effective than shClk1-1, the GL261 glioma cells carrying shClk1-2 was then used for all of the following experiments. To explore the role of Clk1 on BCNU-induced cell apoptosis in glioma cells, activation of caspase-3 and PARP were monitored by western blot analysis. The results showed that BCNU-induced cleaved caspase-3 and poly (ADP-ribose) polymerase (PARP) were markedly reduced in Clk1 knockdown (shClk1-2) GL261 cells (Fig. 2g) .
Since the expression of MGMT, multiple drug resistance 1, and GSTP1 are closely associated with glioma chemoresistance (Sarkaria et al. 2008) , the expression of these genes in Clk1 knockdown and control cells were also compared by RT-PCR. As shown in Fig. 2(h) , the expression of MGMT, multiple drug resistance 1, and GSTP1 were not altered by Clk1 knockdown.
The growth rate has been previously shown to influence sensitivity of glioma cells to anti-cancer drug (Chung et al. 2016) . Thus, the cells' growth rate in Clk1 knockdown and control cells was measured by cell count (Fig. 2i) . The result showed that there was no significant difference in the growth rate between Clk1 knockdown and control cells at indicated time point (24, 48, and 72 h). These results indicated that the chemoresistance of Clk1 knockdown cell was independent of previously known mechanism such as altered expression of multidrug resistance-related genes or growth rate.
Clk1 deficiency resulted in the increased aerobic glycolysis in GL261 glioma cells Increased glycolytic metabolism confers to chemoresistance of malignant tumor cells (Ganapathy-Kanniappan and Geschwind 2013; Suh et al. 2014) . Recently, we have demonstrated that Clk1 was involved in metabolic reprogramming in microglia cells (Gu et al. 2017) . Thus, we next addressed whether Clk1 alters the glycolytic metabolism in glioma cells and how the metabolic reprogramming affects its role in the chemosensitivity of GL261 glioma cells. As shown in Fig. 3(a) and (b), Clk1 knockdown significantly increased the glucose consumption and lactate production in GL261 glioma cells ( Fig. 3a and b) . Meanwhile, the expression of key molecules including glucose transporter 1, hexokinase2 (HK2), LDHA, and PDK1 were all upregulated in Clk1 knockdown GL261 glioma cells (Fig. 3c) . In support, ECAR, an indirect indicator of lactate production and enhanced glycolytic metabolism, was also significantly increased in Clk1 knockdown GL261 cells (Fig. 3d) . We next investigated whether the increased aerobic glycolysis involved in the chemoresistance of Clk1 knockdown GL261 glioma cells. Application of 2-DG, a specific inhibitor of hexokinase (HK) markedly increased the sensitivity of Clk1 knockdown GL261 glioma cells to BCNU (Fig. 3e and f) . Similarly, application of 3-BrPA which is another inhibitor of HK, also increased BCNU-induced cell death in Clk1 knockdown GL261 glioma cells ( Fig. 3g and h ). The inhibition of glycolysis increased chemosensitivity in Clk1 deficient glioma cells was further confirmed in HK2 knockdown by siRNA in Clk1 knockdown cells (Fig. 3i-k) . These results indicated that Clk1 deficiency elicited the metabolic reprogramming that may contribute to the development of chemoresistance in glioma cells.
Clk1 deficiency-triggered aerobic glycolysis and chemoresistance are dependent on the expression of HIF-1a in GL261 glioma cells Hypoxia-inducible factor (HIF)-1a, a pivotal transcription factor that is critical for glycolysis regulation, has already been reported to be associated with chemoresistance in malignant tumor cells (Warfel and El-Deiry 2014) . We therefore examined if Clk1 deficiency-triggered aerobic glycolysis and chemoresistance were dependent on HIF-1a expression. As shown in Fig. 4(a) and (b) , the expression of HIF-1a was up-regulated in Clk1 knockdown glioma cells at both mRNA and protein levels ( Fig. 4a and b) . Knockdown of HIF-1a inhibited HK-2 expression and increased the BCNU-induced cell death in Clk1 knockdown glioma cells ( Fig. 4c and d) , indicating that Clk1 deficiency-triggered aerobic glycolysis and chemoresistance are dependent on HIF-1a expression.
Expression of HIF-1a is mediated by AMPK/mTOR signaling pathway Since the transcriptional expression and protein stability of HIF-1a are regulated by mTOR activation (Hudson et al. 2002) , we addressed if activation of mTOR signaling was involved in Clk1 deficiency-triggered up-regulation of HIF1a in glioma cells. The result showed that knockdown of Clk1 increased mTOR phosphorylation (Fig. 5a upper) , which was further confirmed by the phosphorylation of S6K and S6, the downstream signaling pathways of mTOR (Fig. 5a middle) . Since the activation of mTOR is known to be negatively regulated by AMPK phosphorylation or Fig. 2 Clk1 knockdown reduced sensitivity of GL261 glioma cells to 1,3-Bis (2-chloroethyl)-1-nitrosourea (BCNU) or cisplatin (DDP). GL261 cells was transfected with Clk1 shRNA construct (shClk1-1 or shClk1-2) or control construct (shCtrl), and then the stable transfectants were selected in the presence of G418 (0.8 mg/mL). Total RNA or proteins were isolated from GL261 glioma cells stably expressing shClk1 or shCtrl and then subject to RT-PCR analysis (a) or western blot (b) for detection of Clk1 expression (left). Expression of Clk1 was quantified by densitometric analysis and normalized to a-tubulin (right). GL261 glioma cells stably expressing shClk1 or control was treated with BCNU (0.3-0.7 mM) (c and e) or DDP (0.125-0.2 mM) (d and f) for 24 h, and the cell viability was measured by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. GL261 glioma cells stably expressing shClk1 or control was treated with BCNU (0.2 mM) for 24 h. Total proteins were isolated and then subject to western blot for detection of cleaved Caspase 3 or poly (ADP-ribose) polymerase (PARP) (upper). Expression of Caspase 3 or PARP was quantified by densitometric analysis and normalized to corresponding total protein (lower). (g). Total RNA was isolated and then subject to RT-PCR analysis for assessing the expression of MDR1, GSTP1, and MGMT at mRNA levels (h). GL261 glioma cells stably expressing shClk1 or control construct was plated in 24-well plates (0.5 9 10 4 cells/well) in triplicate. At the indicated times, the cells were detached, and counted by a hemocytometer (i). Data are presented as mean AE SD (n = 3), and are representative of three independent experiments. *p < 0.05, **p < 0.01, compared to control.
positively controlled by Akt phosphorylation (Laplante and Sabatini 2012) , the phosphorylation of these proteins were determined by western blot. The results showed that knockdown of Clk1 in GL261 glioma cells resulted in decreased AMPK phosphorylation without alteration of Akt phosphorylation (Fig. 5a lower) . A critical role of AMPK or Total proteins were isolated and then subject to western blot for detection of expression of GLUT-1, HK2, lactate dehydrogenase A (LDHA), and pyruvate dehydrogenase kinase 1 (PDK1) (left). Protein expression were quantified by densitometric analysis and normalized to a-tubulin (right). (d) Cellular extracellular acidification rate was measured using a Seahorse XFe24 analyzer. GL261 glioma cells stably expressing shClk1 were pre-treated with 2-deoxy-D-glucose (2-DG) (1 mM) (e) or 3-BrPA (0.2 mM) (g) for 24 h, and then the levels of lactate in the cell culture medium were measured by lactate assay kit. GL261 glioma cells stably expressing shClk1 were pre-treated with 2-DG (1 mM) (f) or 3-BrPA (0.2 mM) (h) before 1,3-Bis (2-chloroethyl)-1-nitrosourea (BCNU) incubation (0.2-0.8 mM). After treatment of BCNU for 24 h, the cell viability was measured by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. GL261 glioma cells stably expressing shClk1 were pre-treated with HK2 siRNA or control siRNA (siCtrl) for 48 h, total RNA or proteins were isolated and then subject to RT-PCR analysis (i) or western blot (j) for detection of HK2 expression (upper). Expression of HK2 was quantified by densitometric analysis and normalized to atubulin (lower). After treatment of BCNU (0.2-0.8 mM) for 24 h, the cell viability was assessed by MTT assay (k). Data are presented as mean AE SD (n = 3), and are representative of three independent experiments. *p < 0.05, **p < 0.01, compared to shCtrl or shClk1 cells treated with vehicle or shClk1cells treated with siCtrl.
mTOR signaling on HIF-1a expression in Clk1 knockdown glioma cells was further confirmed by treatment of metformin (AMPK activator) or rapamycin (mTOR inhibitor). Clk1 deficiency-induced mTOR phosphorylation and HIF-1a expression in glioma cells were markedly attenuated by both metformin and rapamycin (Fig. 5b) . We further determined the effect of metformin or rapamycin on chemosensitivity of Clk1 knockdown glioma cells. The result showed that both metformin and rapamycin partially restored chemosensitivity of shClk1 GL261 glioma cells to BCNU (Fig. 5c ). Taken together, our results indicated that Clk1 deficiency-upregulated HIF-1a expression was dependent on the AMPK/ mTOR pathway in glioma cells. Since AMPK is activated by relative increases of AMP or ADP, we compared ADP/ATP ratio between shCtrl and shClk1 GL261 glioma cells. The result revealed that the ADP/ATP ratio was markedly reduced in shClk1 GL261 glioma cells, as compared to that of shCtrl cells (Fig. 5d) . To further confirm the role of Clk1 in chemoresistance, we performed experiments to test the BCNU sensitivity in Clk1 knockdown GL261 glioma cells by transfection of Clk1 cDNA (mutation in siRNA binding site) to re-expression of Clk1 (Fig. 5e) . The results showed that chemosensitivity of Clk1 knockdown GL261 glioma cells was rescued by re-expression of Clk1 (Fig. 5f ).
Clk1 deficiency inhibited mitochondrial respiration that may contribute to GL261 glioma cells chemoresistance Recent evidence suggested that mitochondrial dysfunction can contribute to development of chemoresistance in malignant tumors (Nagy et al. 2015) . To evaluate if Clk1 knockdown altered mitochondrial function (mitochondrial respiration), the OCR was measured by Seahorse XFe24 flux analyzer. Compared with the control cells, Clk1 knockdown GL261 cells significantly decreased maximal OCR (Fig. 6a) , indicating that knockdown of Clk1 inhibits oxygen consumption of glioma cells. To confirm if mitochondrial dysfunction results in chemoresistance of GL261 glioma cells, we next tested the effects of respiration complex Total RNA or proteins were isolated and then subject to RT-PCR analysis (a) or western blot (b) for detection of HIF-1a expression at mRNA or protein levels (left). Expression of HIF-1a was quantified by densitometric analysis and normalized to a-tubulin (right). (c) GL261 glioma cells stably expressing shClk1 or shCtrl was transfected with HIF-1a siRNA or siCtrl for 48 h. Total proteins were isolated and then subject to western blot (upper). Expression of HK2 was quantified by densitometric analysis and normalized to a-tubulin (lower). After treatment of 1,3-Bis (2-chloroethyl)-1-nitrosourea (BCNU) for 24 h, the cell viability was measured by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (d). Data are presented as mean AE SD (n = 3), and are representative of three independent experiments. *p < 0.05, **p < 0.01, compared to shCtrl or shClk1 cells treated with siCtrl. inhibitors on BCNU-induced cell death. The results showed that rotenone (complex I inhibitor), 3-NP (complex II inhibitor), and antimycin (complex III inhibitor) -all inhibited BCNU-induced GL261 glioma cells death ( Fig. 6b-d ). These findings suggested that Clk1-altered mitochondrial respiration may contribute to the development of chemoresistance in glioma cells.
Over-expression of Clk1 increased sensitivity of human glioblastoma cells to BCNU Having shown that Clk1 deficiency in GL261 glioma cells reduced chemosensitivity likely via elevation of AMPK/ mTOR/HIF-1a mediated aerobic glycolysis, the role of Clk1 in human glioblastoma such as T98G and U251 cells, was investigated. Over-expression of Clk1 significantly increased the chemosensitivity of T98G or U251 human glioblastoma cells to BCNU in a dose-dependent manner ( Fig. 7a-d) . We next explored the role of Clk1 in lactate secretion in T98G or U251 human glioblastoma cells. As shown in Fig. 8(a) and (b), over-expression of Clk1 markedly reduced lactate production in T98G or U251 human glioblastoma cells. In addition, pre-treatment with glycolytic inhibitor 2-DG or 3-BrPA significantly enhanced chemosensitivity of T98G or U251 human glioblastoma cells that expressed low level of Clk1 ( Fig. 8c and d) . Likewise, the role of Clk1 on the expression of HIF-1a ( Fig. 8e and f) , activation of AMPK, and mTOR pathways were also determined in T98G or U251 human glioblastoma cells. Similar to the GL261 mouse glioma cells, over-expression of Clk1 enhanced AMPK phosphorylation, reduced phosphorylation of mTOR, and decreased phosphorylation of S6K in T98G or U251 human glioblastoma cells (Fig. 9a and b) . These results indicated that Clk1 regulated sensitivity of glioma cells not only in murine GL261 glioma cells but also in human glioblastoma cells. To explore whether Clk1 expression is regulated by glycolysis or AMPK activation, we tested the effect of glycolytic inhibitor or metformin on Clk1 expression in various glioma cells. The results revealed that both inhibition of glycolysis and AMPK activation did not alter the expression of Clk1 in various glioma cells including U251, T98G, and GL261 glioma cells (Fig. 10) . These results indicated that aerobic glycolysis are not involved in the regulation of Clk1 expression in glioma cells.
Discussion
In this study, we demonstrate that Clk1 expression is correlated with the sensitivity of glioma cells response to BCNU and knockdown of Clk1 resulted in enhanced aerobic glycolysis, which contributes to the chemoresistance of GL261 glioma cells. Clk1 deficiency-induced glycolysis is dependent on the AMPK/mTOR/HIF-1a signaling pathway. Clk1 deficiency-triggered mitochondrial dysfunction also contributes to the chemoresistance of glioma cells.
Resistance to chemotherapeutic agents is a major obstacle to the successful treatment of malignant glioma. Therefore, the development of strategies to reverse the resistance to these agents may enhance the efficacy of malignant glioma treatment (Reagan et al. 2013) . The Clk1 gene encodes mitochondrial hydroxylase that is required for biosynthesis of ubiquinone and plays a key role in the mitochondrial electron transport and production of ROS (Levavasseur et al. 2001) . It is demonstrated that loss-of-function mutation of Clk1 in nematode C. elegans or Clk À/À embryonic stem cell are resistant to cytotoxic agent hemiasterlin or etoposide, respectively (Liu et al. 2005; Zubovych et al. 2010) . Consistent with this, the present study showed that knockdown of Clk1 reduces sensitivity of GL261 glioma cells to BCNU or DDP without changing the expression of multidrug resistance-related genes in those cells and their growth rate. We further demonstrated that either re-expression of Clk1 in Clk1 deficient murine glioma cells or over-expression of Clk1 in human glioblastoma cells enhanced chemosensitivity in glioma cells. We found that Clk1 was differently expressed in glioma cell lines and its expression level was related with chemosensitivity of these glioma cells. The human glioblastoma cell lines T98G (grad IV), U87MG (grad IV), and U251 (grad III) which were previously reported to exhibit strong chemoresistance (Wolff et al. 1999) , have a low level of Clk1 expression. However, there is multiple mechanism involved in the development of chemoresistance of human glioblastoma cells, such as the expression of MGMT, anti-apoptotic gene, multidrug resistance associated gene, and gene mutation (Sarkaria et al. 2008) . For example, T98G expressed high level of MGMT, but U87MG and U251 cells expressed low level of MGMT which makes T98G cells more resistant to alkylating agent temozolomide (TMZ) than U87MG and U251 cells (Alonso et al. 2007) . It is worthy to note that although T98G cell expresses higher level of Clk1 compared to U251 or U87MG cells, it appears to be more resistant to BCNU, indicating that, in addition to Clk1, other mechanisms are implicated in the development of chemoresistance. Therefore, the precise molecular mechanism for regulation of Clk1 expression in glioma cells requires further investigation. Malignant cells consume large amounts of glucose and convert mitochondrial OXPHOS to glycolysis even when oxygen is adequate, as is known as the Warburg effect (Oudard et al. 1996; Dickinson et al. 2013) . The glycolysis intermediates accumulate in tumors and are used to generate metabolic intermediates which are required for the synthesis of nucleotides, amino acids, and fatty acids to sustain cell proliferation and confer a growth advantage allowing malignant cells to survive and grow, especially under chemotherapeutic stresses (Wolf et al. 2010) . Several studies have demonstrated that the expression levels of GLUT1, HK2, and LDHA were correlated with the development of chemoresistance in malignant tumors (Shannon et al. 2003; Ulanovskaya et al. 2011) . It was also demonstrated that several glycolytic inhibitors enhanced the sensitivity of cancer cells to anti-cancer drug (Kuntz et al. 2014) . In this study, we found that Clk1 knockdown promoted aerobic glycolysis in glioma cells, while inhibitions of glycolysis by 2-DG and 3-BrPA or knockdown of HK2 expression abolished Clk1 deficiency-induced resistance to BCNU, suggesting that Clk1 regulate chemoresistance through metabolic reprogramming. This finding reveals that Clk1-regulated metabolic reprogramming plays an important role in the development of chemoresistance in glioma cells, and suggesting that modulation of Clk1 activity may be a potential strategy to prevent the development of glioma chemoresistance.
HIF-1a is a transcriptional factor that plays an important role in the regulation of glucose metabolism in malignant tumor cells (Semenza 2013) . In most tumor cell types,HIF1a promotes metabolic shift from oxidative phosphorylation to glycolysis through activation of glycolytic genes expression including GLUT1, HK, LDHA, and PDK1 (Semenza 2013) . Studies documented that the knockdown of Clk1 in macrophage or microglia results in increased expression of HIF-1a, which may contribute to an enhanced immune response (Wang et al. 2010; Gu et al. 2017) . This study showed that knockdown of Clk1 results in the up-regulation of HIF-1a and inhibition of HIF-1a expression reversed Clk1 deficiency-triggered aerobic glycolysis and chemoresistance of glioma cells. These results suggested that regulating aerobic glycolysis and subsequent chemoresistance of glioma cells by Clk1 are dependent on the expression of HIF-1a.
The mTOR signaling pathway is reported to regulate HIF1a expression in aerobic conditions at both mRNA and protein levels (Hudson et al. 2002; Hu et al. 2012; Wu et al. 2014) . It was demonstrated that the mTOR pathway is regulated by AMPK and Akt pathway. AMPK negatively control mTOR activation whereas Akt postively regulate mTOR activation (O' Neill 2013) . Recently, we demonstrated that AMPK inactivation mediated activation of the mTOR/HIF-1a signaling pathways participate in Clk1 deficiency-triggered aerobic glycolysis in microglia cells (Gu et al. 2017) . Consistently, this study also found that knockdown Clk1 in glioma cells resulted in enhanced phosphorylation of mTOR, S6K, and S6, which appeared to be mediated via inactivation of AMPK. It is therefore reasonable to conclude that Clk1 deficiency-induced HIF-1a expression is likely mediated by AMPK/mTOR pathway in glioma cells. AMPK is activated by at least two upstream kinases. One is the serine-threonine kinase, liver kinase B1 which phosphorylates AMPK in response to cellular stresses such as increase of AMP/ATP or ADP/ATP ratio. In this study, we found that knockdown of Clk1 in GL261 glioma cells markedly reduced ADP/ATP ratio. It was also demonstrated that Ca 2+ /calmodulin-dependent kinase kinase b (CaMKKb) can phosphorylate AMPK response to increased calcium. Since cellular concentration of calcium was controlled by mitochondrial function, we cannot exclude the possibility that AMPK activation by Clk1 knockdown in (2-DG) (1 mM) or 3-BrPA (0.2 mM) before 1,3-Bis (2-chloroethyl)-1-nitrosourea (BCNU) (0.6-1.2 mM) incubation for 24 h and then the cell viability was measured by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Total proteins were isolated from the cells and then expression of HIF1a was detected by western blot (e and f, upper). Expression of HIF-1a was quantified by densitometric analysis and normalized to a-tubulin (e and f, lower). Data are presented as mean AE SD (n = 3), and are representative of three independent experiments. *p < 0.05, **p < 0.01, compared to control. glioma cells is dependent on the CaMKKb. Future works are necessary to explore whether CaMKKb is involved in the mechanisms of Clk1-regulated AMPK activation and the molecular and cellular mechanisms of Clk1 to regulate ADP/ ATP ratio. Furthermore, we found that either glycolysis inhibition or AMPK activation did not change the expression of Clk1 in various glioma cell lines tested, suggesting that Clk1 expression is not dependent on the glycolysis or AMPK activation.
Mitochondrial dysfunction has been involved in the modulation of chemosensitivity (Milane et al. 2011; Nagy et al. 2015) and some mitochondrial mutations can result in chemoresistance in malignant tumors (Green and Reed 1998; Wallace 1999; Zubovych et al. 2010) . It is demonstrated that mitochondrial inhibitor (inhibitor of respiration complexes I, II, and III) reduced sensitivity of wild-type worm to antimitotic drug hemiasterlin (Zubovych et al. 2010) . Previously, it is reported that Clk1 À/+ heterozygous mutants Fig. 9 Over-expression of Clk1 decreased phosphorylation of mechanistic target of rapamycin (mTOR) pathway and increased AMP-activated protein kinase (AMPK) activation in human glioblastoma cells. T98G (a) or U251 (b) glioblastoma cells over-expressing human Clk1 or control were plated in six-well plates (2 9 10 5 cells/ well). Total proteins were isolated from the cells and then expression of phosphorylation of mTOR, S6K, S6, and AMPK was detected by western blot (upper). The phosphorylated proteins were quantified by densitometric analysis and normalized to corresponding total protein (lower). Data are presented as mean AE SD (n = 3), and are representative of three independent experiments. *p < 0.05, **p < 0.01, compared to control. displayed reduced mitochondrial oxygen consumption, mitochondrial electron transport, and mitochondrial ATP production (Lapointe and Hekimi 2008) . Consistent with previous reports, this study showed that Clk1 knockdown displays reduced OCR in glioma cells. Furthermore, we also observed that mitochondrial inhibitor reduced sensitivity of GL261 glioma cells to BCNU. These results suggest that Clk1 deficiency-induced mitochondrial dysfunction was also involved in chemoresistance of glioma cells. Further studies are necessary to evaluate mitochondrial membrane potential of Clk1 knockdown glioma cells and explore the precise molecular mechanism by which Clk1 regulates cell apoptosis pathway in glioma cells. Nevertheless, current data demonstrated that regulation of Clk1 expression may be a potential approach for maintaining the sensitivity of chemotherapy in glioma.
In conclusion, the present data revealed that Clk1 is a critical regulator of glioma metabolic reprogramming, which may, in turn, contribute to the development of chemoresistance. Modulation of Clk1 may provide a novel approach and drug target to glioma chemoresistance.
